A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells
Cell Reports · 2026-11 · 45 (11) · 118212
DOI: 10.1016/j.celrep.2026.118212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-11. Verfasst von Xiaoguang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Discovery Research, AbbVie, Inc., Cambridge, MA 02139, USA. Electronic address: xiaoguang.li@abbvie.com. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Tolerogenic dendritic cells (TolDCs) contribute to immune tolerance and have demonstrated therapeutic potential in early clinical studies of autoimmune diseases. However, the key molecular pathways driving their differentiation and tolerogenic phenotype remain elusive. Here, we investigated the molecular mechanisms underlying the functional status of TolDCs in response to different tolerizing agents and identified CD86 as a consistent and robust marker downregulated in tolerogenic state. CD86 is functionally required for TolDC-mediated suppression of T cell proliferation and cytokine secretion, supporting its use as a surrogate marker of tolerogenic potential. Leveraging CD86 expression as a readout, we performed a genome-wide CRISPR-Cas9 knockout screen and characterized genes associated with TolDC phenotypes. This approach positions UBE2L6 as a regulator of CD86 expression through modulation of an ISG15-USP18-associated pathway, implicating its involvement in tolerogenic functions. These findings describe therapeutically targetable pathways to promote immune tolerance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunology Discovery Research, AbbVie, Inc., Cambridge, MA 02139, USA. Electronic address: xiaoguang.li@abbvie.com.
- Immunology Discovery Research, AbbVie, Inc., Cambridge, MA 02139, USA.
- Former AbbVie employee, Cambridge, MA, USA.
- Genomics Research Center, AbbVie, Inc., North Chicago, IL 60064, USA.
- Immunology Discovery Research, AbbVie, Inc., Cambridge, MA 02139, USA. Electronic address: kanstantsin.katlinski@abbvie.com.
Zitieren
APA
Li, X., Han, T., Chen, L., Suresh, M., Rahimov, F., Gao, C., Wang, J., Ma, R., Stender, J. D., & Katlinski, K. (2026). A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells. Cell Reports, 45(11), 118212. https://doi.org/10.1016/j.celrep.2026.118212
Vancouver
Li X, Han T, Chen L, Suresh M, Rahimov F, Gao C, et al. A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells. Cell Reports. 2026;45(11):118212. doi:10.1016/j.celrep.2026.118212
BibTeX
@article{Li2026,
author = {Li, Xiaoguang and Han, Tiankai and Chen, Liang and Suresh, Megha and Rahimov, Fedik and Gao, Chao and Wang, Jing and Ma, Renze and Stender, Joshua D and Katlinski, Kanstantsin},
title = {A genome-wide CRISPR screening identifies targets that drive tolerogenic dendritic cells},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {11},
pages = {118212},
doi = {10.1016/j.celrep.2026.118212}
}
EUVIMED